Female Reproductive & Breast

Polycystic ovary syndrome: diagnosis and management

Clinical Overview and When to Suspect PCOS

— Increased GnRH pulse frequency → ↑LH:FSH ratio → theca cell androgen overproduction

— Insulin resistance → hyperinsulinemia amplifies ovarian androgen synthesis and suppresses hepatic SHBG, raising free testosterone

— Anovulation from arrested follicular development, producing unopposed estrogen exposure

— Adolescent or adult woman with oligomenorrhea/amenorrhea (cycles >35 days or <8/year)

— Hirsutism, acne resistant to standard therapy, androgenic alopecia

— Infertility or recurrent early pregnancy loss

— Acanthosis nigricans, central obesity, or unexplained weight gain

— Incidental finding of polycystic ovaries on pelvic imaging

PCOS is the most common endocrinopathy in reproductive-age women (8–13% prevalence), characterized by a triad of ovulatory dysfunction, hyperandrogenism, and polycystic ovarian morphology (PCOM).

Pathophysiology centers on:

When to suspect in the outpatient setting:

Step 3 management: PCOS is fundamentally an outpatient longitudinal diagnosis — your job is to confirm it, exclude mimics, then build a chronic-disease care plan addressing menstrual regulation, androgen symptoms, fertility goals, and metabolic risk (T2DM, dyslipidemia, NAFLD, OSA, endometrial cancer).

Rotterdam criteria (most widely used in the US, ESHRE/ASRM endorsed) require 2 of 3: oligo-/anovulation, clinical or biochemical hyperandrogenism, PCOM on ultrasound — after exclusion of other causes.

Board pearl: In adolescents within 8 years of menarche, ultrasound is not used to diagnose PCOS because multifollicular ovaries are physiologic; require both persistent menstrual irregularity AND hyperandrogenism.

High-risk demographics: South Asian women have higher metabolic morbidity at lower BMI; first-degree relative with PCOS or T2DM increases pretest probability.

Counsel that PCOS is a diagnosis of exclusion with lifelong cardiometabolic implications, not merely a fertility or cosmetic issue — framing matters for adherence.

Presentation Patterns and Key History

— Phenotype A (classic): hyperandrogenism + oligo-anovulation + PCOM — highest metabolic risk

— Phenotype B: hyperandrogenism + oligo-anovulation (no PCOM)

— Phenotype C (ovulatory): hyperandrogenism + PCOM with regular cycles

— Phenotype D (non-hyperandrogenic): oligo-anovulation + PCOM — lowest metabolic risk, most controversial

— Menstrual: age of menarche, cycle length variability, last menstrual period, prior pregnancies, contraception use

— Androgenic symptoms: onset and pace of hirsutism (rapid progression suggests tumor), acne distribution, scalp hair thinning, voice deepening, clitoromegaly

— Metabolic: weight trajectory, prediabetes/diabetes, snoring or witnessed apnea (OSA), family history of T2DM/CVD

— Mood: screen for depression, anxiety, and eating disorders — all elevated in PCOS

— Fertility goals: currently desired, future, or not — drives entire treatment algorithm

Classic phenotype: woman aged 15–35 with irregular cycles since menarche, progressive hirsutism along the upper lip, chin, chest, lower abdomen, and inner thighs, plus weight gain centered at the waist.

Four Rotterdam phenotypes (prognosis varies):

Targeted history checklist:

Key distinction: Slowly progressive hirsutism since adolescence = PCOS; rapid virilization over months with deepening voice, clitoromegaly, severe androgenic alopecia → suspect androgen-secreting ovarian or adrenal tumor or Cushing syndrome — escalate workup.

Medication history is essential — valproate, danazol, anabolic steroids, and exogenous testosterone mimic PCOS features.

Board pearl: Always ask about galactorrhea (prolactinoma), heat/cold intolerance (thyroid), striae and proximal weakness (Cushing), and recent stressors or weight loss (functional hypothalamic amenorrhea) — these are the standard PCOS mimics tested on Step 3.

Document menstrual calendar prospectively; recall is unreliable and shapes both diagnosis and endometrial cancer risk assessment.

Physical Exam Findings and Metabolic Assessment

— Blood pressure (HTN present in ~30%)

— BMI and waist circumference (>88 cm in women indicates central adiposity even at normal BMI)

— Assess for orthostatic changes only if symptoms suggest adrenal insufficiency mimic

— Modified Ferriman-Gallwey score ≥4–6 (varies by ethnicity) in 9 body areas defines clinical hirsutism

— Inflammatory acne on jawline, chest, back persisting beyond adolescence

— Female-pattern hair loss (crown thinning, preserved frontal hairline)

— Virilization signs (clitoromegaly >10 mm, temporal balding, deep voice, increased muscle mass) → red flag for tumor, not typical PCOS

— Acanthosis nigricans at neck, axillae, groin — velvety hyperpigmented plaques

— Skin tags (acrochordons)

— Central obesity with abdominal striae (pale, thin — distinguish from violaceous striae of Cushing)

Vitals and anthropometrics:

Hyperandrogenism findings:

Insulin resistance markers:

Pelvic exam usually normal; bimanual may reveal mildly enlarged ovaries but is not required for diagnosis.

Thyroid palpation, breast exam for galactorrhea, and inspection for Cushingoid features (moon facies, dorsocervical fat pad, violaceous striae, proximal muscle weakness) help exclude mimics.

Step 3 management: At every PCOS visit, document BP, BMI, waist circumference, and acanthosis — these drive cardiometabolic screening intensity and are commonly asked as the "next best step" in surveillance.

Screen for obstructive sleep apnea using STOP-BANG in obese patients; OSA prevalence is 5–10× higher in PCOS independent of BMI.

Board pearl: Hirsutism with abrupt onset, rapid progression, or virilization mandates total testosterone and DHEA-S measurement urgently; testosterone >150–200 ng/dL suggests ovarian tumor, DHEA-S >700 µg/dL suggests adrenal tumor — order transvaginal US and adrenal CT respectively.

Mental health screening (PHQ-9, GAD-7) is part of the routine exam given high comorbidity.

Diagnostic Workup — Initial Labs and Imaging

— β-hCG — pregnancy is the #1 cause of amenorrhea

— TSH — hypo- or hyperthyroidism causes menstrual irregularity

— Prolactin — exclude prolactinoma; mild elevations (<50 ng/mL) occur in PCOS

— FSH and LH — exclude premature ovarian insufficiency (high FSH) and hypothalamic amenorrhea (low FSH/LH); LH:FSH >2 suggests but does not confirm PCOS

— Total and free testosterone (free by calculation using SHBG, not direct immunoassay)

— SHBG — typically low in PCOS due to hyperinsulinemia

— DHEA-S — mildly elevated in PCOS; markedly elevated suggests adrenal source

— 17-hydroxyprogesterone (morning, follicular phase) — screen for non-classic congenital adrenal hyperplasia (NCCAH); >200 ng/dL warrants ACTH stimulation test

— 2-hour 75-g oral glucose tolerance test (preferred over A1c alone — more sensitive in PCOS)

— Fasting lipid panel

— LFTs (NAFLD screening)

— Consider vitamin D, given high deficiency prevalence

— PCOM defined (2018 international guideline) as ≥20 follicles per ovary (using high-frequency ≥8 MHz transducer) OR ovarian volume ≥10 mL

— Older threshold of ≥12 follicles is outdated for modern probes

Order labs in the early follicular phase (day 2–5) if cycles permit; otherwise on any day in amenorrheic patients, with pregnancy excluded first.

Mandatory initial panel (rule out mimics + establish diagnosis):

Metabolic baseline (all patients at diagnosis):

Pelvic transvaginal ultrasound:

Key distinction: Anti-Müllerian hormone (AMH) is not yet a stand-alone diagnostic criterion in US guidelines but correlates with follicle count; can substitute for ultrasound in adults only per 2023 international guideline updates.

Board pearl: If 17-OHP, cortisol-related screening, or testosterone are markedly abnormal, do not diagnose PCOS — pursue the alternative diagnosis (NCCAH, Cushing, tumor) first.

Diagnostic Workup — Confirmatory and Advanced Studies

— ACTH (cosyntropin) stimulation test if 17-OHP >200 ng/dL: 17-OHP >1000 ng/dL at 60 min confirms non-classic CAH (21-hydroxylase deficiency)

— 24-hour urinary free cortisol, late-night salivary cortisol, or low-dose dexamethasone suppression test if Cushing features (proximal weakness, violaceous striae, easy bruising, hypertension, hyperglycemia)

— Total testosterone >150–200 ng/dL or DHEA-S >700 µg/dL: transvaginal US ± MRI pelvis (ovarian tumor) and adrenal CT (adrenal tumor)

— Markedly elevated prolactin (>100 ng/mL): pituitary MRI

— In women with prolonged amenorrhea (>3 months) plus risk factors (obesity, age >45, persistent abnormal bleeding), perform transvaginal US for endometrial thickness; if >7 mm in premenopausal anovulatory patient with abnormal bleeding, proceed to endometrial biopsy to exclude hyperplasia or carcinoma

— Repeat OGTT every 1–3 years even if initial normal (annually if obese, family history, or gestational diabetes history)

— Polysomnography if STOP-BANG positive or symptomatic

— Hepatic ultrasound or FIB-4 score if LFTs elevated for NAFLD/MASLD

When initial workup is ambiguous or red flags present, escalate testing:

Endometrial assessment:

Advanced metabolic and cardiovascular workup:

CCS pearl: On the CCS case, after ordering the diagnostic basics (β-hCG, TSH, prolactin, total testosterone, 17-OHP, OGTT, lipid panel, transvaginal US), advance the clock to results, then layer in lifestyle counseling and pharmacotherapy. Don't forget to schedule a follow-up appointment in 3 months.

Key distinction: Insulin levels and HOMA-IR are NOT recommended for routine PCOS diagnosis — they are research tools and do not change management. The OGTT is the clinically actionable test.

Board pearl: Re-evaluate the diagnosis in any patient with rising androgens over time — PCOS androgens should be stable, not progressive.

Risk Stratification and First-Line Management Logic

— Menstrual regulation and endometrial protection

— Hyperandrogenism (hirsutism, acne, alopecia)

— Fertility (currently trying to conceive)

— Metabolic risk reduction (weight, glucose, lipids, BP)

— Quality of life and mental health

— 5–10% weight loss restores ovulation in 50–60% of overweight women

— Mediterranean or low-glycemic-index diet

— ≥150 min/week moderate aerobic + 2 days resistance training

— Smoking cessation, alcohol moderation, sleep hygiene

— Refer to registered dietitian and behavioral health early; consider GLP-1 receptor agonists (semaglutide, liraglutide) when BMI ≥30 or ≥27 with comorbidities — increasingly used off-label and on-label for weight in PCOS

— High-risk features: obesity, T2DM, HTN, dyslipidemia, family history of premature CVD, South/East Asian ethnicity, OSA

— Use ASCVD risk calculator once age 40+, recognizing it underestimates risk in PCOS

— Not seeking pregnancy → combined oral contraceptive (COC) is first-line for cycle control + androgen symptoms

— Seeking pregnancy → letrozole first-line for ovulation induction

— Metabolic predominant or overweight with impaired glucose → add metformin

— Hirsutism inadequately controlled on COC after 6 months → add spironolactone

PCOS management is goal-directed and longitudinal — anchor every plan to the patient's current priority:

Lifestyle modification is first-line for ALL phenotypes, regardless of BMI:

Stratify cardiometabolic risk:

Decision tree for pharmacotherapy:

Step 3 management: Always reassess at 3-month intervals — menstrual response to COC is rapid; hirsutism takes 6 months to assess because of hair cycle length; metabolic improvements take 3–6 months.

Board pearl: Endometrial protection is non-negotiable in any anovulatory patient — they need either cyclic progestin, COC, or levonorgestrel IUD to prevent endometrial hyperplasia and carcinoma, a 2–6× elevated risk in PCOS.

Pharmacotherapy — First-Line Drug Regimens

— Mechanism: suppress LH → ↓ovarian androgens; ↑SHBG → ↓free testosterone; provide cyclic withdrawal bleeds (endometrial protection)

— Preferred progestins: norgestimate, desogestrel, drospirenone (lower androgenic activity); avoid levonorgestrel/norethindrone if hirsutism is prominent

— Drospirenone has antiandrogen and antimineralocorticoid effects — good for hirsutism but monitor potassium if on ACEi/ARB/spironolactone

— Contraindications: migraine with aura, smoker ≥35, uncontrolled HTN, VTE history, active breast cancer, decompensated liver disease — use progestin-only options or LNG-IUD instead

— Start 500 mg daily with meals, titrate by 500 mg/week to 1500–2000 mg/day to minimize GI side effects

— Modestly restores ovulation, reduces weight (~2–3 kg), improves insulin sensitivity, lowers progression to T2DM

— Add to COC when BMI ≥25 or glucose intolerance present

— Hold for contrast procedures if eGFR <30; contraindicated when eGFR <30

— 50–200 mg/day; androgen receptor antagonist

— Always combine with reliable contraception — teratogenic (feminization of male fetus)

— Monitor potassium at baseline and after dose changes; caution with ACEi/ARB

— Effect takes 6 months; combine with mechanical hair removal (laser, electrolysis) for faster cosmetic benefit

— Eflornithine cream slows facial hair growth

— Topical retinoids, benzoyl peroxide, clindamycin for acne

Combined oral contraceptives (COCs) — first-line for non-fertility-seeking patients:

Metformin — first-line for metabolic features:

Spironolactone — second-line for hirsutism/acne:

Topical therapies:

Board pearl: Letrozole (aromatase inhibitor, 2.5–7.5 mg days 3–7) is the first-line ovulation induction agent — superior live-birth rates vs clomiphene per the PPCOS II trial, especially in obese women.

Step 3 management: Counsel that clomiphene is now second-line; gonadotropins or IVF are reserved for letrozole failure or other infertility factors. Refer to reproductive endocrinology after 3–6 failed ovulation cycles.

Procedures and Expanded Pharmacology

— Step 1: Lifestyle + 5–10% weight loss → may restore ovulation alone

— Step 2: Letrozole 2.5 mg days 3–7, increase by 2.5 mg/cycle up to 7.5 mg if no ovulation; monitor with mid-luteal progesterone or ovulation predictor kits

— Step 3: Clomiphene citrate 50–150 mg days 3–7 if letrozole fails or unavailable

— Step 4: Add metformin (synergistic, especially with obesity)

— Step 5: Gonadotropins (FSH ± LH) with cycle monitoring by reproductive endocrinology — risk of ovarian hyperstimulation syndrome (OHSS) and multiple gestation

— Step 6: In vitro fertilization (IVF) — definitive option; bypasses ovulatory defect

— Reserved for clomiphene/letrozole-resistant patients, often during diagnostic laparoscopy

— Comparable live-birth rates to gonadotropins without OHSS risk or multiple gestation

— Risks: adhesions, premature ovarian insufficiency if overdone — operator-dependent

— Consider when BMI ≥40, or ≥35 with comorbidities (T2DM, OSA, HTN)

— Sleeve gastrectomy and RYGB improve ovulation, menstrual regularity, fertility, and metabolic profile

— Avoid pregnancy for 12–18 months postoperatively due to rapid weight loss and micronutrient risks

— GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) — improve weight, insulin resistance, and ovulation; discontinue ≥2 months before conception (animal teratogenicity signals)

— Inositols (myo-inositol + D-chiro-inositol) — supplements with modest insulin-sensitizing data

Ovulation induction algorithm (fertility-seeking patients):

Laparoscopic ovarian drilling (LOD):

Bariatric/metabolic surgery:

Emerging agents:

CCS pearl: When ordering ovulation induction on CCS, schedule mid-luteal (day 21–24) progesterone to confirm ovulation; progesterone >3 ng/mL = ovulation occurred. Repeat for 3–6 cycles before escalating.

Board pearl: OHSS (ascites, pleural effusion, hemoconcentration, thromboembolism) is rare with letrozole/clomiphene but a key complication of gonadotropins and IVF — recognize it on stems.

Special Populations — Renal/Hepatic Impairment and Older Patients

— Hyperandrogenism often improves with age as ovarian function declines, but metabolic risk persists and accelerates

— Cycles may regularize in the 40s — do not interpret as "cure"; continue cardiometabolic surveillance lifelong

— Postmenopausal PCOS patients have higher rates of T2DM, HTN, dyslipidemia, NAFLD, and possibly CVD

— Continue annual BP, lipids, glucose; consider statins per ASCVD guidelines (often qualify earlier than the general population)

— Metformin: dose-reduce when eGFR 30–45 (max 1000 mg/day), avoid if eGFR <30

— Spironolactone: monitor potassium closely; avoid when eGFR <30 or K+ >5

— COCs: generally safe in mild CKD but avoid in advanced CKD due to HTN and VTE risk — use LNG-IUD or progestin-only methods

— COCs contraindicated in active hepatitis, cirrhosis with decompensation, history of cholestasis of pregnancy

— Metformin: avoid in acute hepatitis or decompensated cirrhosis (lactic acidosis risk)

— Statins generally safe with monitoring; avoid in decompensated disease

— Metformin remains first-line

— GLP-1 RAs and SGLT2 inhibitors increasingly preferred — weight loss, CV and renal benefits

— Avoid sulfonylureas (weight gain) and pioglitazone (weight gain, fluid retention, fracture risk in women)

PCOS in perimenopause and beyond:

Renal impairment:

Hepatic impairment:

Patients with comorbid T2DM:

Step 3 management: In a perimenopausal woman with a history of PCOS, do not stop screening — order annual lipid panel, BP, A1c or fasting glucose, and assess for endometrial cancer symptoms (postmenopausal bleeding always warrants TVUS ± biopsy).

Board pearl: PCOS confers a 2–6× lifetime risk of endometrial cancer — Step 3 stems featuring a 50-year-old woman with PCOS history and abnormal bleeding should prompt endometrial biopsy, not reassurance.

Special Populations — Pregnancy and Adolescents

— Diagnose using two criteria only: persistent oligo-/amenorrhea (≥2 years post-menarche) AND clinical or biochemical hyperandrogenism

— Ultrasound is NOT used — multifollicular ovaries are physiologic

— Label "at risk for PCOS" if only one criterion met and re-evaluate at 8 years post-menarche

— Treatment: lifestyle, COCs for cycle control and acne/hirsutism, metformin if metabolic features

— Optimize weight, glucose, BP, and thyroid before conception

— Folic acid 400–800 µg/day (1 mg if T2DM); 4 mg if prior NTD

— Discontinue spironolactone (teratogenic), statins, ACEi/ARB, GLP-1 RAs

— Continue metformin until pregnancy confirmed; can continue into pregnancy in select cases (data evolving)

— Gestational diabetes (2–3×) — screen with early OGTT in first trimester, repeat at 24–28 weeks

— Preeclampsia and gestational HTN (2×)

— Preterm birth, miscarriage, cesarean delivery

— OHSS if conception followed gonadotropin/IVF cycle

— Macrosomia and NICU admission

— Low-dose aspirin 81 mg starting 12–16 weeks for preeclampsia prophylaxis if additional risk factor

— Frequent BP monitoring, early GDM screening, growth surveillance

— Repeat 75-g OGTT at 4–12 weeks if GDM occurred; then every 1–3 years lifelong

— Resume contraception/cycle management; LNG-IUD safe immediately postpartum

— Counsel on breastfeeding benefits for both maternal and infant metabolic health

Adolescent PCOS (within 8 years of menarche):

Preconception counseling:

Pregnancy complications elevated in PCOS:

Antepartum management:

Postpartum:

Key distinction: In adolescents, acne and irregular cycles alone do not diagnose PCOS — both are common physiologic post-menarche; require persistence and biochemical or marked clinical hyperandrogenism.

Board pearl: A pregnant patient with PCOS history should receive early GDM screening at the first prenatal visit with HbA1c or fasting glucose, then standard 24–28 week OGTT — do not wait.

Complications and Adverse Outcomes

— Infertility — anovulatory subfertility; 70–80% of anovulatory infertility cases

— Increased miscarriage rate (independent of obesity)

— Endometrial hyperplasia and carcinoma — 2–6× lifetime risk from chronic unopposed estrogen exposure

— Type 2 diabetes — 3–5× risk; develops a decade earlier than non-PCOS peers

— Metabolic syndrome — present in 30–50%

— Non-alcoholic fatty liver disease (NAFLD/MASLD) — present in up to 40%, often independent of BMI

— Dyslipidemia — high triglycerides, low HDL, atherogenic LDL pattern

— Hypertension prevalence elevated

— Subclinical atherosclerosis markers (CIMT, coronary calcium) elevated

— Long-term CVD mortality data mixed but signal toward elevated MI and stroke risk

— Venous thromboembolism risk elevated, compounded by COC use

— Obstructive sleep apnea 5–10× more common, even at lower BMI — independently worsens insulin resistance

— Depression, anxiety, eating disorders (binge eating) — 3× elevated

— Body image disturbance, sexual dysfunction

— Annual screening (PHQ-9, GAD-7) is standard of care

— Persistent acne, scarring, hirsutism, androgenic alopecia → psychosocial burden

— OHSS with gonadotropin/IVF — ascites, pleural effusion, hemoconcentration, VTE; severe cases require hospitalization, albumin, anticoagulation

— Multiple gestation with ovulation induction

Reproductive complications:

Metabolic complications:

Cardiovascular complications:

Sleep and respiratory:

Psychiatric and quality of life:

Dermatologic:

Procedure-related:

Board pearl: Postmenopausal bleeding or prolonged amenorrhea (≥3 months) with abnormal bleeding in a PCOS patient → endometrial biopsy, not just observation. Do not miss endometrial cancer.

Step 3 management: Every PCOS visit should include the "6 M's" screen: Menses, Metabolic (glucose/lipids/BP), Mass index, Mood, Maternity goals, Malignancy surveillance (endometrial).

When to Escalate Care — Consult or Inpatient Triage

— Failed ovulation induction after 3–6 cycles of letrozole/clomiphene

— Suspected tubal, uterine, or male-factor infertility

— Need for gonadotropins, IVF, or ovarian drilling

— Recurrent pregnancy loss workup

— Diagnostic uncertainty (suspected NCCAH, Cushing, androgen-secreting tumor)

— Difficult-to-control T2DM, severe insulin resistance

— Concomitant thyroid or pituitary pathology

— Endometrial hyperplasia with atypia or endometrial carcinoma on biopsy

— Severe nodulocystic acne (consider isotretinoin — pregnancy prevention via iPLEDGE), refractory hirsutism, scarring alopecia

— BMI ≥40, or ≥35 with comorbidities, failed medical weight management

— Positive PHQ-9 ≥10 or GAD-7 ≥10, suicidal ideation, suspected eating disorder

— Severe OHSS: tense ascites, pleural effusion, dyspnea, oliguria, hemoconcentration (Hct >45%), WBC >15K, hyponatremia, hyperkalemia, renal/hepatic dysfunction, or VTE → admit for IV fluids, albumin, paracentesis, thromboprophylaxis with LMWH, monitor closely

— DKA or HHS in PCOS patient with undiagnosed T2DM → ICU-level care per standard protocols

— Acute heavy abnormal uterine bleeding with anemia requiring transfusion → admit for high-dose estrogen IV, tranexamic acid, possible D&C

— VTE on COC → anticoagulation, discontinue COC permanently, switch to non-estrogen method

PCOS is overwhelmingly outpatient, but specific scenarios require escalation:

Refer to Reproductive Endocrinology:

Refer to Endocrinology:

Refer to Gynecologic Oncology:

Refer to Dermatology:

Refer to Bariatric Surgery:

Refer to Mental Health:

Inpatient triage scenarios:

CCS pearl: On CCS, if a PCOS fertility patient presents with severe abdominal distension and dyspnea after gonadotropin therapy → admit, order CBC, BMP, LFTs, coagulation, CXR, pelvic US, start LMWH thromboprophylaxis, IV crystalloids, consider albumin and paracentesis. Consult REI urgently.

Board pearl: Do not continue ovulation induction if the patient develops moderate-severe OHSS — escalate, do not push another cycle.

Key Differentials — Same-Category (Endocrine) Causes

— Both hypo- and hyperthyroidism cause menstrual irregularity and infertility

— TSH is part of every PCOS workup

— Galactorrhea, amenorrhea, headaches, visual field defects

— Mild prolactin elevation (<50) common in PCOS; >100 ng/mL suggests prolactinoma → MRI pituitary

— Treat with cabergoline or bromocriptine

— Most common: 21-hydroxylase deficiency

— Mimics PCOS exactly: hirsutism, irregular cycles, infertility

— Screen with morning follicular 17-OHP >200 ng/dL; confirm with ACTH stim test (17-OHP >1000 at 60 min)

— Treatment differs: low-dose glucocorticoid (hydrocortisone or prednisone)

— Higher prevalence in Ashkenazi Jewish, Hispanic, Mediterranean populations

— Central obesity, moon facies, violaceous striae, proximal weakness, hypertension, hyperglycemia, easy bruising

— Screen with 24-hour urinary free cortisol, late-night salivary cortisol, or low-dose dexamethasone suppression

— Ovarian (Sertoli-Leydig, granulosa, hilar cell) or adrenal

— Rapid virilization, testosterone >150–200 ng/dL, DHEA-S >700 µg/dL

— Image with transvaginal US + MRI pelvis (ovarian) or adrenal CT

— Amenorrhea before 40 with elevated FSH (>25 IU/L on two occasions ≥4 weeks apart)

— Estrogen-deficient, not androgen-excess; hot flashes, vaginal dryness

— Workup: karyotype, FMR1 premutation, adrenal/thyroid autoantibodies

— Low FSH and LH, low estradiol; triggered by stress, weight loss, excessive exercise (female athlete triad)

— No hyperandrogenism; treatment is restoration of energy balance

Thyroid disease:

Hyperprolactinemia / prolactinoma:

Non-classic congenital adrenal hyperplasia (NCCAH):

Cushing syndrome:

Androgen-secreting tumors:

Premature ovarian insufficiency (POI):

Functional hypothalamic amenorrhea:

Key distinction: PCOS has normal-to-high LH, low SHBG, mildly elevated androgens, normal estradiol, whereas hypothalamic amenorrhea has low LH/FSH, low estradiol, no hyperandrogenism. Both cause amenorrhea but the labs separate them definitively.

Board pearl: Always rule out pregnancy, prolactinoma, thyroid disease, NCCAH, and Cushing before labeling a patient with PCOS — these are the five mimics tested.

Key Differentials — Other-Category Causes

— Hirsutism with regular ovulatory cycles and normal androgens

— Increased peripheral 5α-reductase activity in hair follicles

— Treat symptomatically with spironolactone, COCs, eflornithine, laser

— Biochemical hyperandrogenism without ovulatory dysfunction or PCOM

— Some overlap with Rotterdam Phenotype C; managed similarly to PCOS for symptoms

— Anabolic steroids, exogenous testosterone, danazol, valproate, cyclosporine, phenytoin, minoxidil — review medication list before diagnosis

— Postpartum and lactation can produce transient menstrual irregularity

— Always rule out with β-hCG before any further workup

— Luteoma of pregnancy, hyperreactio luteinalis — gestational hyperandrogenism resolving postpartum

— Polyps, adenomyosis, leiomyomas, malignancy, coagulopathy, endometrial, iatrogenic, not yet classified

— PCOS is "ovulatory dysfunction" (O) — but coexisting fibroids or polyps may confuse the picture; imaging clarifies

— HAIR-AN syndrome: hyperandrogenism, insulin resistance, acanthosis nigricans — severe variant

— Type A and B insulin receptor mutations — very rare, profound acanthosis and virilization

— Can cause menstrual irregularity, hirsutism, insulin resistance, but with characteristic features (frontal bossing, jaw enlargement, hand/foot growth, ring tightening, headaches)

— Screen with IGF-1

— Anorexia → hypothalamic amenorrhea

— Binge eating and bulimia overrepresented in PCOS — they can coexist, not exclude

Idiopathic hirsutism:

Idiopathic hyperandrogenism:

Medication-induced:

Pregnancy and pregnancy-related:

Structural gynecologic causes of abnormal bleeding (PALM-COEIN):

Insulin resistance syndromes:

Acromegaly:

Eating disorders:

Step 3 management: When a patient presents with hirsutism + irregular cycles, the workflow is: pregnancy test → TSH, prolactin, FSH, LH, total testosterone, DHEA-S, 17-OHP, OGTT → ultrasound → diagnose by exclusion using Rotterdam.

Board pearl: Acanthosis nigricans alone is a sign of insulin resistance, not a diagnosis — also seen in obesity, T2DM, internal malignancy (especially gastric adenocarcinoma when sudden/extensive in older adults).

Secondary Prevention and Long-Term Plan

— Annual BP measurement; goal <130/80 in those with comorbidities

— Lipid panel every 1–3 years; statin per ASCVD risk (often qualify earlier due to PCOS-amplified risk)

— OGTT or HbA1c every 1–3 years (annually if obese, prior GDM, family history); prediabetes warrants metformin and lifestyle intensification

— Weight maintenance: 5–10% loss meaningful; sustain via long-term dietitian engagement, GLP-1 RAs if indicated

— NAFLD/MASLD surveillance: LFTs, FIB-4, hepatic US if elevated

— Endometrial protection in any anovulatory patient: COC, cyclic medroxyprogesterone (10 mg × 10–14 days every 1–3 months), or levonorgestrel IUD (most effective for endometrial protection and offers contraception)

— Annual menstrual review; investigate any abnormal bleeding promptly

— Counsel that return of ovulation is unpredictable — pregnancy can occur even with irregular cycles

— All methods acceptable; LNG-IUD particularly valuable

— Endometrial: clinical (no routine biopsy); biopsy if abnormal bleeding, persistent thickened endometrium, age >45 with risk factors

— Cervical and breast cancer screening per USPSTF (PCOS does not change these)

— PCOS generally protects against osteoporosis (high estrogen, hyperandrogenism) — but assess vitamin D and lifestyle as routine

PCOS is a chronic disease requiring lifelong care. Build a longitudinal plan at diagnosis:

Cardiometabolic prevention:

Reproductive prevention:

Contraception (separate from cycle control):

Cancer surveillance:

Bone health:

Vaccinations: routine adult schedule, HPV through 26 (shared decision-making 27–45), influenza, COVID, Tdap

Mental health follow-up: PHQ-9, GAD-7 annually

Step 3 management: At every annual visit, complete the PCOS surveillance bundle: BP, BMI, waist, A1c/glucose, lipids, LFTs, menstrual history, mood screen, contraceptive needs, fertility goals. Document explicitly.

Board pearl: Even after menopause, PCOS patients carry their cardiometabolic and endometrial cancer risk — surveillance does not stop at 50.

Follow-Up, Monitoring, and Counseling

— 3 months after starting new pharmacotherapy: assess tolerability, menstrual response, side effects, labs (K+ if on spironolactone, A1c if on metformin)

— 6 months: reassess hirsutism (hair cycle length), metabolic markers

— Annually thereafter: full PCOS surveillance bundle

— More frequent visits during fertility treatment (cycle-based) or pregnancy

— COC: BP at 3 months and annually; reassess VTE risk factors; ask about migraine pattern

— Metformin: B12 level every 2–3 years (associated deficiency); renal function annually

— Spironolactone: potassium and creatinine at baseline, 1 month after dose change, then annually; pregnancy avoidance counseling

— GLP-1 RAs: GI tolerability, signs of pancreatitis, gallbladder symptoms; lipase if symptomatic

— Letrozole/clomiphene: mid-luteal progesterone to confirm ovulation; ultrasound monitoring per REI protocols

— Set realistic expectations: PCOS is manageable, not curable; symptoms wax and wane

— Hirsutism takes 6 months to respond — patience and combination with cosmetic measures

— Weight loss is the highest-yield intervention — even modest reductions transform outcomes

— Mental health is part of the disease, not a personal failing

— Fertility is usually achievable — most women with PCOS conceive with appropriate treatment

— Primary care quarterbacks; loop in gynecology, endocrinology, REI, dermatology, mental health, dietitian as needed

— Use shared electronic problem list to ensure continuity

Visit cadence:

Monitoring parameters by therapy:

Counseling pillars:

Patient education resources: PCOS Awareness Association, Endocrine Society patient guides; encourage peer support

Care coordination:

Step 3 management: Document fertility intentions at every visit — they change over time and shift the entire treatment plan (e.g., a woman on spironolactone planning conception must transition off and start letrozole).

CCS pearl: Schedule the 3-month follow-up explicitly on CCS for any new PCOS pharmacotherapy — missing this lowers the management score.

Ethical, Legal, and Patient Safety Considerations

— Spironolactone is teratogenic (feminization of male fetus) — document discussion of contraception requirement and obtain agreement before prescribing; use highly effective contraception (COC, LNG-IUD, implant) concurrently

— Isotretinoin for severe acne requires iPLEDGE enrollment: two negative pregnancy tests before initiation, monthly tests during therapy, two forms of contraception, monthly prescriber and patient attestations — a frequently tested Step 3 safety pathway

— Statins, ACEi/ARB, GLP-1 RAs must be discontinued preconception

— Adolescents can usually consent to contraception, STI testing, and reproductive care without parental notification in most states — know your state's minor consent laws

— Balance confidentiality with safety; involve parents when clinically indicated and consented

— Hirsutism, weight, infertility carry psychological burden — use non-stigmatizing language ("weight," not "obese"; "menstrual irregularity," not "abnormal")

— Screen for and address eating disorders before recommending weight loss; aggressive weight discussion can trigger disordered behaviors

— Adolescent-to-adult transition is high-risk for loss to follow-up; coordinate structured handoff with named adult provider, problem list, treatment history

— Postpartum transition: ensure repeat OGTT 4–12 weeks postpartum and re-engagement with longitudinal PCOS care — a common Step 3 gap

— Fertility therapy coverage varies widely; counsel on costs early

— GLP-1 RAs often face prior authorization — document medical necessity

— Discuss success rates, multiple-gestation risk, OHSS risk, financial implications before initiating gonadotropins or IVF

— Screen for intimate partner violence during reproductive care visits

— Suicidal ideation triggers same-day mental health linkage

Informed consent for teratogenic therapy:

Adolescent confidentiality:

Body image and stigma:

Transition of care:

Insurance and access:

Shared decision-making for fertility:

Mandatory considerations:

Board pearl: A common Step 3 stem: a teenager started on spironolactone presents 4 months later with a positive pregnancy test — the answer is stop spironolactone immediately, counsel on teratogenic risk, refer for prenatal care, and review contraception adequacy at the prescription stage.

High-Yield Associations and Rapid-Fire Clinical Facts

Rotterdam criteria = 2 of 3: oligo-/anovulation, hyperandrogenism, PCOM — after exclusion of mimics

Adolescents: do not use ultrasound; require both menstrual and androgen criteria

PCOM threshold: ≥20 follicles per ovary or ovarian volume ≥10 mL (modern probes)

LH:FSH ratio >2 is suggestive but not diagnostic

SHBG is low in PCOS → calculate free testosterone, not direct assay

Letrozole > clomiphene for ovulation induction (PPCOS II trial), especially with obesity

Metformin reduces T2DM progression, modestly aids ovulation, weight, insulin resistance

Spironolactone + reliable contraception; takes 6 months to assess hirsutism response

GLP-1 RAs transforming weight and metabolic management in PCOS

Endometrial cancer risk: 2–6× elevated — protect with progestin

Gestational diabetes risk 2–3× — early OGTT in pregnancy

Preeclampsia, preterm birth, miscarriage all elevated

OSA prevalence 5–10× elevated, even at lower BMI

NAFLD/MASLD in up to 40% — screen LFTs

17-OHP >200 ng/dL → ACTH stim to rule out NCCAH

Testosterone >150–200, DHEA-S >700 → image for tumor

HAIR-AN syndrome = severe insulin-resistant PCOS variant

Acanthosis nigricans = insulin resistance marker

Drospirenone COCs have antiandrogen and antimineralocorticoid effects

Avoid levonorgestrel/norethindrone COCs if hirsutism predominant

Bariatric surgery reverses many PCOS features at BMI ≥35–40

OHSS is the major iatrogenic complication of gonadotropins/IVF

Mental health comorbidity (depression, anxiety, eating disorders) — screen routinely

Endometrial biopsy for any anovulatory PCOS patient with prolonged abnormal bleeding

Postmenopausal bleeding in PCOS history = endometrial cancer until proven otherwise

CCS pearl: The five labs that "make or break" a PCOS workup on CCS: β-hCG, TSH, prolactin, total testosterone, 17-OHP, plus OGTT for metabolic baseline.

Board pearl: Step 3 questions love the transition points — adolescent to adult, preconception to pregnancy, postpartum to longitudinal care, premenopause to menopause. Know what changes at each.

Board Question Stem Patterns

Stem 1 — Classic diagnosis: 24-year-old woman with irregular cycles since menarche, BMI 32, mild hirsutism on chin and upper lip, mild acne. Labs: TSH normal, prolactin 18, FSH 5, LH 12, total testosterone 65, 17-OHP 110, β-hCG negative. Best next step? → Pelvic ultrasound to assess PCOM (or, if adult, accept clinical diagnosis and start workup of metabolic comorbidities with OGTT and lipids).

Stem 2 — Rule out NCCAH: 19-year-old with hirsutism and oligomenorrhea; 17-OHP 320 ng/dL morning value. Best next step? → ACTH stimulation test (cosyntropin); not "diagnose PCOS."

Stem 3 — Endometrial cancer risk: 38-year-old PCOS patient with no period for 6 months, BMI 36, irregular spotting. Best next step? → Endometrial biopsy (not just progestin challenge).

Stem 4 — Ovulation induction: 28-year-old PCOS patient wants to conceive, BMI 33. First-line agent? → Letrozole.

Stem 5 — Hirsutism inadequately controlled: Patient on COC × 9 months with persistent hirsutism. Next step? → Add spironolactone (with continued contraception).

Stem 6 — Pregnancy in patient on spironolactone: 22-year-old presents with positive β-hCG while on spironolactone for PCOS-related hirsutism. Best next step? → Discontinue spironolactone immediately, counsel on teratogenic risk, initiate prenatal care, early OGTT screening.

Stem 7 — Virilization: 30-year-old with 6-month rapid hirsutism, deepening voice, clitoromegaly, testosterone 280 ng/dL. Best next step? → Transvaginal ultrasound (and adrenal imaging) — suspect androgen-secreting ovarian tumor; not "start COC."

Stem 8 — OHSS: PCOS patient post-gonadotropins develops abdominal distension, dyspnea, oliguria, Hct 48%. Best next step? → Admit, IV fluids, thromboprophylaxis, paracentesis as needed, consult REI.

Stem 9 — Adolescent PCOS overdiagnosis: 14-year-old, 18 months post-menarche, irregular cycles, mild acne, ultrasound with "multifollicular ovaries." Best next step? → Reassure and re-evaluate over time; do not diagnose PCOS.

Stem 10 — Postpartum follow-up: PCOS patient with GDM during pregnancy delivered 8 weeks ago. Best next step? → 75-g OGTT at 4–12 weeks postpartum; then every 1–3 years.

Board pearl: Recurring trap — choosing "PCOS" before excluding pregnancy, thyroid, prolactin, NCCAH, Cushing, and tumors. Always sequence the workup before committing to diagnosis.

Step 3 management: Pay attention to what the patient wants next (cycle control vs. fertility vs. cosmetic vs. metabolic) — the "best next step" depends on the goal stated in the stem.

One-Line Recap

PCOS is a lifelong, exclusion-based diagnosis (Rotterdam: 2 of 3 — oligo-anovulation, hyperandrogenism, PCOM) whose Step 3 management hinges on aligning treatment to the patient's current goal — cycle control, androgen symptoms, fertility, or metabolic risk reduction — while delivering longitudinal cardiometabolic surveillance and endometrial protection.

— Not seeking pregnancy → COC ± spironolactone, add metformin for metabolic features

— Seeking pregnancy → letrozole first-line, then clomiphene, gonadotropins, IVF; lifestyle and 5–10% weight loss for everyone

— Severe obesity/T2DM → consider GLP-1 RAs and bariatric surgery

Diagnose: Confirm Rotterdam criteria after excluding pregnancy, thyroid disease, hyperprolactinemia, NCCAH (17-OHP), Cushing, and androgen-secreting tumors; skip ultrasound in adolescents within 8 years of menarche.

Treat by goal:

Protect the endometrium in every anovulatory patient (COC, cyclic progestin, or LNG-IUD); biopsy any prolonged abnormal bleeding.

Surveil for life: annual BP, BMI, waist, A1c/OGTT every 1–3 years, lipids, LFTs (NAFLD), mood screen, OSA screen; early GDM screening in pregnancy; postpartum OGTT at 4–12 weeks.

Watch for red flags that aren't PCOS: rapid virilization, testosterone >150–200, DHEA-S >700, 17-OHP >200 — pursue tumor or NCCAH workup.

Patient safety highlights: spironolactone is teratogenic and requires contraception; isotretinoin requires iPLEDGE; discontinue statins, ACEi/ARB, GLP-1 RAs preconception; recognize OHSS as a fertility-treatment emergency requiring admission.

Board pearl: The most testable Step 3 PCOS theme is transition points — adolescence, preconception, pregnancy, postpartum, and perimenopause — where the management plan must be actively rewritten, not passively continued.